BRCA1 and breast cancer: In the POSH study, which evaluated the effect of germline BRCA1/2 mutation on BC survival in YW diagnosed in the United Kingdom between 2000 and 2008, the 5-year OS was 83.8% among mutation carriers and 85.0% among noncarriers; the 10-year OSs were 73.4% and 70.1%, respectively [29].